Debiopharm’s new focus

Debiopharm Group has been using its strategic venture fund to get up to speed on potentially transformational technologies. Now that the cancer and infectious disease focused specialty pharma has built up companion diagnostics expertise internally and via investments made by Debiopharm Innovation Fund, it is turning the fund’s attention to big data and new therapeutic modalities.

The fund’s Tanja Dowe told BioCentury Debiopharm launched Innovation Fund in 2008 to gain a better understanding of companion diagnostics and personalized medicine. ...